Adding sodium-glucose co-transporter 2 inhibitors to insulin treatment for type 2 diabetes: A combined analysis of clinical trials

A meta-analysis of seven trials involving 4235 patients found that SGLT2 inhibitors with insulin therapy led to a mean reduction in HbA1c of -0.56%.

• SGLT2 inhibitor treatment was associated with a reduction in fasting plasma glucose by -0.95 mmol/L.
• Patients experienced a mean body weight reduction of -2.63 kg and a decrease in insulin dose by -8.79 IU.
• There was a 36% increased risk of drug-related adverse events, with urinary tract infections rising by 29% and genital infections by 357%.
• No significant increase was noted in overall adverse events, serious adverse events, adverse events leading to discontinuation, or hypoglycaemia events.
• No incidents of diabetic ketoacidosis were reported.

Simplified